The efficacy of NPs in the CML leukemic model was proven, and the results suggested that the Ab@Tf-Cou6-PLGA NPs can suppress CML leukemogenesis in vivo (Fig. 6). This evidence concerns the gene TF and chronic myelogenous leukemia, BCR-ABL1 positive.